Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension
These pooled results, representing 174.71 patient-years in the studies, demonstrate that treatment with rozanolixizumab in patients with gMG was well tolerated, and TEAEs were consistent and did not increase in incidence over repeated cycles in this patient population.
Authors
- Artur Drużdż (ORCID: https://orcid.org/0000-0002-4479-4135)
- Kimiaki Utsugisawa (ORCID: https://orcid.org/0000-0001-9373-8167)
- Tuan Vu (ORCID: https://orcid.org/0000-0003-0724-0210)
- Irene Pulido‐Valdeolivas (ORCID: https://orcid.org/0000-0003-0188-2458)
- Renato Mantegazza (ORCID: https://orcid.org/0000-0002-9810-5737)
- Maryam Gayfieva
- Sabrina Sacconi (ORCID: https://orcid.org/0000-0002-0246-1455)
- Franz Woltering
- Vera Bril (ORCID: https://orcid.org/0000-0002-5805-4883)
- Julian Großkreutz (ORCID: https://orcid.org/0000-0001-9525-1424)
- Thaïs Tarancón
- Ali A. Habib (ORCID: https://orcid.org/0000-0003-3432-9747)
- John Vissing
Institutions
- University of Copenhagen (DK)
- University Health Network (CA)
- Université Côte d'Azur (FR)
- University of California, Irvine (US)
- University of South Florida (US)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Centre Hospitalier Universitaire de Nice (FR)
- National Hospital Organization Hanamaki Hospital (JP)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
- UCB Pharma (Germany) (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Journal of Neuromuscular Diseases
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1177/22143602241308181
- Citations
- 7
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 9.72
Funders
- Amgen
- AstraZeneca
- Sanofi
- Biogen
- Alexion Pharmaceuticals
- Regeneron Pharmaceuticals
- Japan Blood Products Organization
- Grifols
- Genentech
- Sanofi Genzyme